Skip to content
Screener

Discontinued — last reported Q2 '23

Debt-to-equity at other companies

Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
0.2×+0.1×
Opko Health logo
Opko HealthOPK
0.0×
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
0.3×+0.1×
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
0.1×0.0×
Roivant Sciences logo
Roivant SciencesROIV
0.0×
CorMedix logo
CorMedixCRMD
0.0×

Other financials

Income statement

See full
Revenue$74.3M+88.0%
Gross profit$59.2M+71.7%
Operating income-$4.0M+93.4%
Net income-$17.6M+76.8%
EPS (diluted)-$0.21+80.0%

Balance sheet

See full
Cash & equivalents$182.5M+22.0%
Total debt$167.1M-18.9%
Total equity-$344.3M+15.2%
Total assets$327.1M+30.7%

Cash flow

See full
Operating cash flow-$1.9M+96.9%
CapEx$44.0K-54.6%
Free cash flow-$2.0M+96.9%

Valuation

See full
Market cap$691.7M-5.2%
Enterprise value$676.34M-13.9%
P/S2.9×-3.5×

Profitability

See full
Gross margin82.9%-4.0pp
Operating margin-17%-8.2pp
Net margin-41.3%-19.1pp
FCF margin-15.4%-7.4pp

Returns & leverage

See full
Return on equity-147.9%
Current ratio1.9×-0.5×

Where this comes from

Calculated from Phathom Pharmaceuticals, Inc.’s reported figures.

Based on the most recent quarter.

The source filing: Phathom Pharmaceuticals, Inc.’s 10-Q, filed August 10, 2023. Open the filing →

Filed
Aug 10, 2023
Fiscal quarter
Q2 FY2023
Calendar quarter
Q2 2023
Accession
0000950170-23-040977

FAQ

What is Phathom Pharmaceuticals, Inc.'s debt-to-equity?
Phathom Pharmaceuticals, Inc. (PHAT) reported debt-to-equity of 5.6× in Q2 2023.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Phathom Pharmaceuticals, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude